These agents have demonstrated significant efficacy in MAPK-driven pLGGs and PNs, as highlighted by recent FDA approvals of dabrafenib/trametinib and selumetinib for the upfront treatment of inoperable pLGGs and NF1-associated PNs, respectively, in the pediatric population. Here, NF1 is linked to paraneoplastic neurologic syndrome.